STUDYING THE CHRONIC TOXICITY OF SULPHAPORIN
Keywords:
Keywords: drug Sulfoparin, chitosan, chronic toxicity, cumulative properties, atherosclerosis.Abstract
Abstract: For the first time, a comprehensive set of preclinical experimental studies of the new therapeutic drug "Sulfoparin," developed by the Institute of Chemistry and Physics of Polymers of the Academy of Sciences of the Republic of Uzbekistan, was conducted. The investigation established that under chronic exposure for an uninterrupted duration of 3 months, the administration of the drug at doses of 500, 100, and 25 mg/kg of body weight does not provoke any pathological alterations within the organisms of the experimental animals. Subsequent morphological examinations confirmed that no statistically or clinically significant differences were present in the structural integrity of the internal organs between the experimental and control groups. Consequently, Sulfoparin does not induce dystrophic, necrobiotic, or inflammatory tissue changes in the animal models.
References
1.Gus'kova, T. A. (2008). Toxicology of medicinal substances. Moscow, 27-30.
2.Inoyatova, F. Kh., Kutlikova, G. M., Milusheva, R. Yu., et al. (2011). Some mechanisms of the hypocholesterolemic action of sulfoparin. Vestnik TMA, (3), 19-22.
3.Inoyatova, F. Kh., Rashidova, S. Sh., Kutlikova, G. M. (2013). Correction by sulfoparin of endothelial dysfunction in rabbits with hypercholesterolemia. International Journal of Applied and Fundamental Research, (1), 36-40.
4.Instruction for preclinical safety testing of pharmacological agents. (2000). Tashkent.
5.Kerch, G. (2015). The Potential of Chitosan and Its Derivatives in Prevention and Treatment of Age-Related Diseases. Marine Drugs, 13(4), 2158–2182. https://doi.org/10.3390/md13042158
6.Cited by: 156
7.Kutlikova, G. M. (2012). Effect of sulfoparin on indices of the nitric oxide system in experimental hypercholesterolemia. Vrach Aspirant, 4(53), 39-43.
8.Liang, B., Cai, X.-Y., & Gu, N. (2021). Marine Natural Products and Coronary Artery Disease. Frontiers in Cardiovascular Medicine, 8. https://doi.org/10.3389/fcvm.2021.739932
9.Cited by: 24
10.Rashidova, S. Sh., & Milusheva, R. Yu. (2009). Chitin and chitosan. Bombyx mori. Synthesis, properties and application. Tashkent, Fan, 193-242.
11.Guidelines for the experimental (preclinical) study of new pharmacological substances, methods of pharmacological preclinical research. (2005). (Ed. R. U. Khabriev). Moscow, 699-709.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal